Core Viewpoint - Ferroptosis is a newly discovered iron-dependent form of programmed cell death that plays a significant role in the development of various diseases, including cancer, and is emerging as a promising new strategy for cancer treatment [2][4]. Group 1: Research Findings - The study published by the teams from Columbia University and the University of Pittsburgh reveals a non-canonical ferroptosis pathway mediated by the GPX1-OSBPL8 axis, which does not require external inducers like erastin or RSL-3 [3][4]. - This non-canonical pathway is part of the natural tumor suppression mechanism mediated by p53, driven by phosphatidic acid (PA) peroxidation induced by reactive oxygen species (ROS) [4][8]. Group 2: Mechanism of Action - The mechanism involves the recruitment of GPX1 to the endoplasmic reticulum (ER) by OSBPL8, where GPX1 reduces oxidized PA to prevent ferroptosis [9][10]. - The study identifies the endoplasmic reticulum as a key site for the initiation of non-canonical ferroptosis, contrasting with classical ferroptosis that primarily focuses on the plasma membrane [10]. Group 3: Implications for Cancer Treatment - The findings suggest that targeting the GPX1-OSBPL8 signaling axis with small molecule inhibitors could selectively induce ferroptosis in tumors, representing a promising cancer therapy strategy [15][16]. - The research enhances understanding of how p53 suppresses tumors through mechanisms like ferroptosis, providing new insights into natural anti-tumor immunity [17]. - The expression levels of OSBPL8 and GPX1 may serve as biomarkers to predict cancer sensitivity to ferroptosis-inducing therapies [17].